Plasma cell differentiation is a tightly regulated process that requires appropriate T cell helps to reach the induction threshold. To further understand mechanisms by which T cell inputs regulate B cell fate decision, we investigate the minimal IL-2 stimulation for triggering human plasma cell differentiation in vitro. Here we show that the timed repression of BACH2 through IL-2-mediated ERK/ELK1 signalling pathway directs plasma cell lineage commitment. Enforced BACH2 repression in activated B cells unlocks the plasma cell transcriptional program and induces their differentiation into immunoglobulin M-secreting cells. RNA-seq and ChIP-seq results further identify BACH2 target genes involved in this process. An active regulatory region within the BACH2 super-enhancer, under ELK1 control and differentially regulated upon B-cell activation and cellular divisions, helps integrate IL-2 signal. Our study thus provides insights into the temporal regulation of BACH2 and its targets for controlling the differentiation of human naive B cells.
A well-characterised gene regulatory network governs the transition of a naive B cell precursor to either a plasma cell or a memory B cell within secondary lymphoid organs 1, 2 . Following antigen-priming B cells enter into longlasting interactions with antigen-specific CD4+ helper T cells at the border of T and B zones 3 . These precursors of T follicular helper cells provide a plethora of signals, costimulatory molecules and cytokines, that can promote B-cell survival, proliferation, and B cell commitment into plasma cells, germinal centre (GC) cells or memory B cells 4 . Temporal dynamic of cell signalling pathways regulating the transcription factor network and influencing B cell fate decision still remains to be investigated. It is suggested that transcriptional repression dominates the program leading to plasma cell differentiation [5] [6] [7] . Indeed, B cell transcription factors are collectively involved in repressing PRDM1/BLIMP1 expression, the multitasking transcription factor in plasma cells 8, 9 . The downregulation of PAX5 early after B-cell activation occurs independent of BLIMP1, suggesting that PAX5 could be the trigger of plasma cell differentiation 10 . IRF4 and IRF8 are proposed to antagonise each other for regulating the initial bifurcation in activated B cell fate 11 . Alternatively, evidences showed that the level of BACH2 instructs B cells to undergo differentiation into either plasma cells or memory cells 6, 12, 13 . BACH2 binds to MARE motifs and cooperates with BCL6 on PRDM1 promoter 14, 15 . However, additional targets of BACH2 beyond PRDM1 during the transition from activated B cells to plasma cells must be elucidated. Moreover, the precise mechanisms regulating BACH2 expression in activated B cells remain unknown despite the description of a super-enhancer in the BACH2 locus 16, 17 .
Difficulties to study signal integration during B cell terminal differentiation originate from heterogeneous and asynchronous cellular responses to differentiation-inducing stimuli [18] [19] [20] . Indeed, antigen affinity and the various co-stimuli of the complex microenvironment that are integrated in a spatial and temporal dynamic manner affect the differentiation process in cascade. In this context, obtaining sufficient number of primary activated B cells, which are rare and transient in vivo, is problematic. Many aspects of human plasma cell differentiation are recapitulated in a primary culture system combining B-cell receptor (BCR) signal, Toll like receptor activation and T cell helps (CD40L and cytokines) 21, 22 . Naive B cells undergo class-switch recombination (CSR) and give rise to plasma cells under these defined conditions. T cell-produced interleukin-2 (IL-2) is one early minimal input required for eliciting differentiation in this model system, independently from proliferation and survival effects 21 . The underlying mechanism involves the extracellular signal-regulated kinase (ERK1/2) signalling pathway. Accordingly, mice models have confirmed the critical role of interleukins and ERK signalling in the initiation of plasma cell differentiation 23 . ERK signalling pathway was shown to be involved in immune cell cycle progression and survival 24 , but its function in terminal differentiation is still controversial, as opposing effects of BCR-induced ERK activation for plasma cell differentiation have both been described in vitro 25, 26 .
Here we study the function of IL-2-induced ERK signalling for plasma cell lineage commitment. We take advantage of a controlled and well-defined in vitro model of the human plasma cell differentiation 21, 22 to catch the transient states of B-cell activation and to follow single-cell destiny. We establish that IL-2-ERK-ELK1 signalling pathway overcomes the repressive forces that block plasma cell differentiation. We identify BACH2 and its target genes as major effectors of the IL-2-ERK-ELK1 signalling pathway for controlling B cell terminal differentiation. Our results suggest a molecular switch of ELK1 acting within the BACH2 super-enhancer to fine-tune BACH2 expression. In conclusion, our data add to the understanding of BACH2 temporal regulation and function in the process of human B-cell activation with important implications for plasma cell differentiation efficiency.
Results
Heterogeneity of B cell response to IL-2 stimulation. Both, human peripheral blood CD19 + CD27 − CD10 − (mainly naive B cells) and highly pure mature ABCB1 transporter-positive naive B cells selected based on their capacity to extrude the mitotracker green fluorescent dye 27, 28 , were differentiated into plasmablasts (CD20 lo CD38 hi ) and plasma cells (CD138 + ) after 7 days of culture (Fig. 1a ). This differentiation process combines B-cell activation initiated by BCR cross-linking, CpG synthetic oligonucleotides and CD40L, followed by a day-2 to day-4 (D2 −D4) expansion of heterogeneous cell populations differing in their proliferative and differentiation capacities. At D4, cell division tracking using carboxyfluoroescein diacetate succinimidyl ester (CFSE) distinguished CFSE hi from CFSE lo activated B cell populations. The later population has previously been shown to differentiate into plasma cells when primed with IL-2 or IL-15, in the first 48 h of culture 21 . To address the ability of antigenprimed B cells to respond to transient IL-2 signal, we performed kinetic experiments. By D3 most of the cells were unresponsive to IL-2 while a short IL-2 stimulation at D2 conferred plasma cell differentiation ability to their progeny ( Fig. 1b ). However, among D4 CFSE lo cells, only a subset gained the capacity to differentiate into plasma cells. Thus, to escape the averaging caused by B cell heterogeneity we implemented single-cell QRT-PCR to compare the D4 CFSE lo cells that were primed with IL-2 with the nonprimed ones. Unsupervised clustering analysis defined a minor subset of cells (30%) among the IL-2 primed cells characterised by the significant downregulation of B cell identity factors including CD20, BACH2, BCL6, SPIB, IRF8 and PAX5, p < 10 −4 (ANOVA) and the upregulation of plasma cell factors PRDM1 and XBP1s, p < 10 −3 (Fig. 1c, Supplementary Fig. 1 ). These committed cells had efficiently integrated IL-2-mediated STAT5 activation as demonstrated by the upregulation of the STAT5 target IL2RA, p < 0.005 (ANOVA). In agreement with the role of IL-2 in triggering ERK signalling that mediates plasma cell fate commitment 21 , the specific ERK-associated MAPKAPK3 was upregulated in these cells, p < 10 −4 (ANOVA). To link this signature with the ability of the cells to differentiate, the cell surface CD25 protein (IL2RA) was used to discriminate the committed cells at D4 within the CFSE lo subset cultured in presence of IL-2 ( Fig. 1d ). CFSE lo CD25 hi cells and the CD25 lo counterpart were sorted and put back in culture for an additional 48 h prior differentiation monitoring by flow cytometry (Fig. 1e ). On average, 76% ± 5% (n = 5) of the CFSE lo CD25 hi cells underwent differentiation whereas less than 10% of plasmablasts (9.8% ± 4%) emerged from the CFSE lo CD25 lo . Importantly, this was not due to differences in survival as shown by the absolute number of plasmablasts generated in each condition ( Fig. 1f ). Thus the heterogeneity in B cell responses results from differences in early IL-2 signal integration.
BACH2 silencing mimics IL-2-triggered differentiation. We previously showed that IL-2-induced ERK signalling leads primarily to a downregulation of BACH2 21 . We thus monitored its expression in two culture conditions, with or without IL-2 added at D0 ( Fig. 2a ). Relative gene expression analysis showed a marked decrease of BACH2 independently of IL-2 stimulation within the first 48 h of culture. Its expression increased significantly at D3 and in the D4 and D5 proliferative subsets in the absence of IL-2, p < 0.01 (Mann−Whitney test). In contrast IL-2 stimulation repressed BACH2 expression between D2 and D4. This temporal regulation of BACH2 was confirmed at the Fig. 1 A minimal early and transient IL-2 signal confers plasma cell differentiation ability to human naive B cells. a Experimental design to differentiate primary naive B cells (NBCs) into plasma cells (PCs). Activation of peripheral blood mature naive B cells was initiated by BCR cross-linking (anti-BCR), CpG and CD40L during 4 days followed by cell washing and induction of terminal differentiation into plasma cells with IL-2, IL-4 and IL-10 over 3 days. Antigen-primed naive B cells have 2-day window (in red) for acquisition of early T cell help in the form of IL-2 which is required to recruit B cells into the plasma cell differentiation program. b Kinetic experiments of IL-2 stimulation to determine the time window (in day, D) and the minimal duration (in hours, h) for B cell to acquire differentiation ability. IL-2 was added in the medium at the indicated day. Neutralising antibodies against IL-2 or IL2 receptors were used to block IL-2 signalling and isotype antibodies were used as controls. Results are the mean of plasma cell numbers with the s.d. quantified at D7 by flow cytometry and fixed to 100 for the condition corresponding to 48 h of IL-2 stimulation (black bar) to normalise between experiments (n = 5). c Single-cell QRT-PCR analysis in the D4-CFSE lo subset of cells that were primed with IL-2 (in blue, n = 175) or not (in grey, n = 110) at D2. The heatmap shows the spectrum of normalised Ct values with a global Z-score: red indicates high level of expression and green indicates low level of expression. Nonhierarchical clustering corresponding to 16 selected genes is shown. Two clusters of cells can be identified with on the left the nascent fraction of plasma cell progenitors showing induced plasma cell transcription factors expression in green linked to an IL-2 signature (IL2RA expression), concomitant with B cell factors repression in red. d Heterogeneity of CD25 (IL2RA) expression analysed by flow cytometry in the D4-CFSE lo subset of cells. Cell division visualised by CFSE dilution at D4 is similar in IL-2 treated and non-treated cells (IL2 and No IL2, respectively). Among CFSE lo cells, CD25 was upregulated in a subset of cells that were cultured in presence of IL-2 (CD25 hi ). e IL-2-primed cells, sorted at D4 based on CFSE dilution and CD25 expression from gates in d, were put back in culture to assess differentiation into plasma cells (CFSE lo CD38 hi ) monitored by flow cytometry at D6, in comparison with their non-sorted counterpart (Total IL2-primed) and the control cells cultured without IL-2 (Total No IL2). One experiment representative of 5 is shown. f Absolute numbers of DAPI negative cells (Live cells) and CFSE lo CD38 hi plasmablasts generated from 10 5 CFSE lo CD25 lo cells (in green) or CFSE lo CD25 hi cells (in purple) sorted at D4 from gates in d, and put back in culture for 2 more days (mean ± s.e.m, n = 5). For experiments shown in b and f, *p < 0.05, **p < 0.01, ***p < 0.005, NS: No significant differences, two-tailed unpaired Student's t-test NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01475-7 ARTICLE protein level (Fig. 2b, c) and raised the possibility that BACH2 may control the engagement of B cells in the differentiation path. To test this hypothesis, we used small interfering RNAs (siBACH2) to transiently inhibit BACH2 expression at D2 through to D4. Knockdown efficiency was controlled by immunoblotting 2 days after electroporation ( Fig. 2d , Supplementary  Fig. 2a ). Consistent with the known regulation of PRDM1 by BACH2, an unimpeded BLIMP1 expression was observed in BACH2 deficient cells. At the mRNA level the expression of the plasma cell-specific transcription factors PRDM1 and XBP1s was upregulated (p < 0.05, t-test) whereas the expression of the B cellspecific transcription factors BCL6, PAX5, SPIB and IRF8 did not show any significant difference compared with the control IL-2primed cells at D4, suggesting that BACH2 targets primarily the plasma cell transcriptional program ( Fig. 2e ). We next explored plasma cell differentiation by flow cytometry at D7 (Fig. 2f ). BACH2 inhibition significantly increased the capacity of IL-2primed cells to differentiate (p < 0.005, Mann−Whitney test). More importantly, BACH2 inhibition was sufficient to drive differentiation in the absence of IL-2. Naive B cells were stimulated with IL-2 during the activation phase (black bars) or not (No IL2, white bars). Expression in naive B cells (D0) was fixed to 100 and the experiments repeated on 6 different B cell donors. b Representative western blot for BACH2 and BLIMP1 protein levels at the indicated days of naive B cells culture. β-ACTIN was used as loading control. Values are the average fold changes in the expression levels of BACH2 normalised to β ACTIN for three independent experiments. c BACH2 protein levels in different subsets of D3-naive B cells stimulated or not with IL-2 for 24 h. Cells were sorted according to CFSE dilution and Hoechst (H) staining. CFSE hi H − corresponds to the non-proliferative subset. β-ACTIN served as loading control. This analysis was repeated two times. Values are the average fold changes in the expression levels of BACH2 normalised to β-ACTIN levels. d Protein expression levels of BACH2 and BLIMP1 analysed by immunoblotting, β-ACTIN was used as loading control. The efficiency of BACH2 inhibition with siRNA (siBACH2) was monitored at D4, 48 h after cell electroporation. Non-targeting siRNA (siCTL) was used as control. Values are the average fold changes in the expression levels of BACH2 normalised to β-ACTIN levels for four independent experiments. e Fold change in gene expression levels analysed by QRT-PCR in D4-IL-2-primed cells that were electroporated on D2 with siBACH2. Expression levels of three independent experiments were normalised to expression levels in the control cells (IL2-siCTL). f Flow cytometry analysis of CD38 hi CFSE lo plasmablasts generated at D7 following IL-2 priming (IL2) or in absence of IL-2 priming (No IL2) and electroporated with siBACH2 or siCTL at D2. The absolute numbers of plasmablasts were quantified by flow cytometry for seven independent experiments. Results were normalised to the IL2-siCTL condition arbitrary fixed to 100 for all the experiments. Values in a, e, f are shown as means ± s.e.m., *p < 0.05, **p < 0.01, ***p < 0.005, NS: No significant differences, Mann−Whitney test was used for a and f, two-tailed unpaired Student's t-test for e
We then studied the kinetic of the differentiation. Only few plasmablasts emerged from the No IL2-siBACH2 condition at D5 (Fig. 3a ). The maximum rate was obtained at D6 and maintained at D7. At that time plasma cell stage was reached for a small percentage of cells indicated by CD138 expression (9% ± 1.2; n = 5, Fig. 3b ). Time course of immunoglobulin M (IgM) secretion ( Fig. 3c) , and of B cell and plasma cell transcription factors expression confirmed the kinetic of the differentiation (Fig. 3d, e ). In coherence with the differentiation process triggered by IL-2 priming, differentiated cells induced by siBACH2 displayed low levels of PAX5 and IRF8 expression and high levels of BLIMP1 and IRF4 as compared to naive B cells. Moreover, differentiated . Cells were primed with IL-2 when specified and electroporated at D2 with siBACH2 or the control siRNA. Corresponding isotypes were used as negative staining control. e Western blot analysis of BACH2, PAX5 and BLIMP1 expression by D4 and D7 sorted plasmablasts (CD38 hi ) and non-differentiated cells (CD38 lo ) that were primed or not with IL-2 and electroporated at D2 with siBACH2 or the control siRNA. f Cytospin and Giemsa staining of plasmablasts generated from BACH2 deficient naive B cells (No IL2-siBACH2) compared to controls. Representative cells are shown (×630 objective, scale bar 20 μm). They displayed features of plasmablasts (arrows), the nucleus is eccentric comparable to plasmablasts generated from naive B cells primed with IL-2 (IL2-siCTL). g Assessment of immunoglobulin class switching in CD38 hi cells at D7 generated from naive B cells deficient from BACH2 (No IL2-siBACH2) or cells that were primed with IL-2 (IL2-siCTL). Data are presented as percentage of positive cells for intracellular staining of IgM and IgG evaluated by flow cytometry. Means ± s.e.m. of four independent experiments. Significant differences are shown. For experiments shown in c and g *p < 0.05, **p < 0.01, NS: non-significant differences, two-tailed unpaired Student's t-test cells induced by siBACH2 displayed morphological features of plasmablasts studied by Giemsa staining (Fig. 3f ), but were mainly IgM ( Fig. 3g ). To demonstrate that BACH2 inhibition did not affect the proliferation capacity of activated B cells in vitro, we performed ModFit analysis on CFSE-stained B cells (Supplementary Fig. 2b ). Together with 5-ethynyl-2′-deoxyuridine (EdU) and active caspase 3 labelling experiments we showed that BACH2 deficiency did not affect activated B cell expansion, survival, or proliferation ( Supplementary Fig. 2c ). Altogether these results suggest that the mechanism triggering plasma cell differentiation in BACH2-deficient B cells was independent of a proliferation or precocious differentiation effect. Furthermore, differentiation remained dependent of the differentiation stimuli anti-BCR, CpG and CD40L ( Supplementary Fig. 2d ). Finally to show the specificity of the BACH2 effect, we inhibited the expression of other crucial B cell identity factors including PAX5 and IRF8 identified previously downregulated by IL-2-mediated ERK activation 21 . Their transient repression did not confer plasma cell differentiation ability to activated B cells ( Supplementary  Fig. 2e ). Taken altogether our data confirm the key role played by BACH2 in blocking the plasma cell differentiation program.
BACH2 is a key effector of IL-2/ERK signalling. We then wanted to determine whether BACH2 mediates the effect of IL-2/ ERK signalling on plasma cell differentiation. To this end, we used MEK inhibitor (MEKi) to temporally and partially inhibit ERK activity at D2 in IL-2-primed cells, at a concentration that did not interfere with cellular proliferation but inhibited their ability to differentiate many divisions later 21 . We first validated that BACH2 expression, repressed by IL-2, was restored by ERK inhibition at the protein level ( Fig. 4a ). Then, D2 cells were transfected with siBACH2, treated with MEKi and subsequently stimulated with IL-2. At D4, BACH2 expression levels were assessed. Partial inhibition of ERK signalling significantly restored BACH2 expression in IL-2-primed cells, p < 0.05 (t-test) and siBACH2 reduced BACH2 expression to a level similar to that in IL-2-primed cells (Fig. 4b) . Strikingly, the ability of MEKi-treated cells to differentiate into plasmablasts was significantly rescued with the siBACH2, p < 0.05 (t-test, Fig. 4c ). These findings indicate that BACH2 is a key downstream target of IL-2 signalling.
BACH2 controls IL-2-driven transcriptional programs. To characterize the transcriptional program involved in the commitment towards plasma cell, we compared the RNA-seq gene expression profiles of D4 IL-2-primed cells (the CFSE lo CD25 hi cells, Fig. 1d ) to the D4 CFSE lo siBACH2 cells. As control we took the D4 CFSE lo cells obtained in absence of IL-2. We established a list of 656 genes that were differentially expressed between the IL-2-committed cells and controls (445 genes upregulated and 211 genes downregulated, FC > 1.4 and Benjamini-Hochberg adjusted p-value (p.adj) < 0.05, Wald test), and a list of 333 genes that were differentially expressed between siBACH2-committed cells and controls (148 genes upregulated and 185 genes downregulated, FC > 1.4 and p.adj < 0.05, Wald test). Both lists were then compared and genes in common represented in the Venn diagrams ( Fig. 5a , Supplementary Fig. 3 and Supplementary Data 1). We observed significant overlaps between IL-2 and BACH2 signatures confirming the major contribution of BACH2 in IL-2-triggered plasma cell fate commitment (p < 5.10 −5 for upregulated genes and p < 0.05 for downregulated genes, hypergeometric distribution). The IL-2 signature was highly enriched in transcripts induced in pre-plasmablasts 29 demonstrating that IL-2 signalling confers broad changes in gene expression associated with plasma cell differentiation ( Fig. 5b) . Interestingly, the strongest siBACH2 effect in committed cells was the upregulation of metabolic genes followed by genes devoted to cellular processes such as cell communication, transport, cell cycle and proliferation, cellular component organisation and immune response ( Fig. 5c ).
Identification of BACH2 target genes. To infer the direct targets of BACH2, we mapped genome-wide BACH2 binding sites using ChIP-seq. To this end, we used activated B cells after 3 days of culture without IL-2; at that time BACH2 expression was increased ( Fig. 2a, c) . We took siBACH2-cells as control. After normalisation, 7883 regulatory regions were obtained compared with 1439 for the control-siBACH2 ( Fig. 6a ). We observed extensive binding at intergenic and intronic regions ( Supplementary Fig. 4 ), while 20% of regulatory regions were located in gene promoters and enriched at transcription start sites (TSS, Fig. 6b ). Motif enrichment analysis identified BACH2 consensus motif that embeds AP-1 binding sites ( Fig. 6c ). We then performed BETA analysis to integrate BACH2 bindings with differentially expressed genes identified above in the BACH2 repression condition. A repressive function for BACH2 was predicted, p < 0.05 (Kolmogorov−Smirnov test, Fig. 6d ). Hereafter we focused our analysis on the 165 upregulated genes in the siBACH2 condition (FC > 1, p.adj < 0.05, Wald test), 105 genes were predicted to be direct targets of BACH2 ( Fig. 6e , Supplementary Data 2). Motif analysis of these genes demonstrated enrichment of binding sites for both B and plasma cell transcription factors (Fig. 6f ). ChIP-seq data confirmed BACH2 binding to PRDM1 locus and inferred new targets linked to the commitment. Of particular interest was the ferrochelatase gene FECH required for haeme synthesis (Fig. 6g ). Haeme homoeostasis plays a key role in plasma cell fate determination and CSR and high concentration of haeme inhibits BACH2 function 30 . Interestingly in T cells BACH2 was found to bind the haeme oxigenase gene HMOX1 that in contrast to FECH is involved in haeme degradation 31 . Here we confirmed the binding of BACH2 in HMOX1; however, the binding was not affected in the siBACH2-cells, in line with our transcriptomic data showing no induction of HMOX1 transcripts in the siBACH2 condition ( Fig. 6g) . Thus, FECH upregulation may be involved in haeme accumulation inhibiting BACH2 function in siBACH2 cells, a regulatory loop that may explain why a small difference in BACH2 expression level may tilt the balance in favour of plasma cell differentiation.
Three members of the dual-specific phosphatases (DUSP) family were identified as targets of BACH2 and found upregulated in the committed signature: DUSP4, DUSP5 and DUSP16 suggesting that the ERK pathway was ultimately under the control of inhibitory molecules in both commitment conditions. Indeed, Dusp5 is required for murine plasma cell differentiation, inhibiting BCR-mediated ERK activation 25 .
Four transcription factors commonly upregulated in committed cells were bound by BACH2: ID2, TOX2, PIR and ATF5. ATF5 has a well-established pro-survival activity, regulating MCL1 expression which is essential for GC formation 32 . Members of the BCL2 family were also part of the BACH2 signature: the anti-apoptotic BCL2L1 (BCLX L ) previously described upregulated in GC B cells 32 , and the pro-apoptotic member BCL2L15 whose expression was downregulated, revealing BACH2 contribution to a balance of the apoptotic signalling pathway. Other genes critical for GC homoeostasis were part of the BACH2 program such as S1PR2 involved in GC B cell clustering and survival 33 .
ELK1 controls BACH2 expression. To understand the mechanism by which IL-2 regulates BACH2 expression, we searched for factors regulated by the ERK pathway and whose inhibition restores BACH2 expression. Yasuda et al. 23 provided evidences in mouse models for the control of Blimp1 expression by ERK/ELK1 signalling pathway. To test whether ELK1 is involved in IL-2-triggered plasma cell differentiation, we first realized western blot analysis that demonstrated phosphorylation of ELK1 by IL-2 stimulation, in an ERK-dependent manner (Fig. 7a ). Next, we implemented siRNA experiments against ELK1 at D1 to inhibit its expression prior to IL-2 stimulation. Knockdown efficiency was verified 2 days after B-cell electroporation at the transcript and protein levels ( Fig. 7a Fig. 7b ). In contrast BACH2 and IRF8 expression levels were significantly increased recapitulating the effects observed with MEKi, suggesting that IL-2-mediated ELK1 phosphorylation can suppress the expression of BACH2. In accordance with this finding, we observed a marked reduction in plasmablast generation in the siELK1 condition at D7, independently from a proliferation effect reinforcing the ELK1/BACH2 axis ( Fig. 7c, Supplementary Fig. 5b ).
ELK1 binds BACH2 intron 1 within a region of open chromatin. In silico motif search for transcription factor binding sites identified an ELK1 binding motif in the first intron of BACH2 with an exact match with matrix consensus used by MatInspector ( Fig. 7d ). This region is highly CpG rich and shows more than 70% local nucleotide sequence identity between mouse and human ( Supplementary Fig. 6a ). Moreover, the sequence surrounding ELK1 binding motif (hg19: 91004796-91006944) was predicted to be a robust enhancer by the FANTOM5 project 35 , located in a super-enhancer structure identified by H3K27ac loading 16, 17 ( Supplementary Fig. 6b ). This region was thus hereafter called BACH2 enhancer. We demonstrated an in vivo binding of ELK1 to this putative enhancer by chromatin immunoprecipitation followed by QPCR (ChIP-QPCR) in IL2primed B cells collected at D3 (Fig. 7e ). We also assessed binding of ELK1 to loci previously described in the literature including binding occurred within an open chromatin region, H3K9ac, H3K4m1, H3K27m1 and H3K27ac were studied by ChIP-QPCR. All these histone marks were present in the proximal promoter region of BACH2 and in the enhancer (Fig. 7f ). Moreover we examined p300 binding by ChIP-QPCR since it is a highly accurate means for identifying enhancers and their associated activities 36 . In line with an enhancer region, we observed marked enrichment of p300 binding at D3 (Fig. 7f) . Interestingly, p300 time course analysis during naive B-cells activation mimicked, to some extent, BACH2 mRNA variations ( Supplementary Fig. 6c ).
We then wanted to know whether ELK1 DNA-binding was modulated by IL-2 stimulation. To this end we performed ChIP-QPCR analyses in D3 cells that were stimulated or not with IL-2 ( Supplementary Fig. 6d ). No significant differences were observed between these two conditions, in agreement with previous studies demonstrating that ELK1 can be bound in the absence of stimulus [37] [38] [39] [40] . Thus we hypothesised that IL-2/ERK may modify the transcriptional activity of ELK1.
Mapping of a functional BACH2 enhancer in activated B cells.
We decided to detail the functional DNA regulatory sequence by luciferase reporter assay in the context of primary human naive B cell activation. The BACH2 proximal promoter 41
Binding events / 1000 cells ARTICLE (minP BACH2, −725; +146) ligated upstream from the nanoluciferase coding sequence (NanoLuc) demonstrated a 4.2 ± 0.2 (n = 15) fold more transcriptional activity than the promoterless NanoLuc vector (pNL1.1), whatever the time point of B-cell electroporation (from D0 to D3). As minP BACH2 did not respond substantially to the B-cell activation cocktail, it was used to test the transcriptional activity of ELK1. The enhancer region (+1265; +1493) was inserted in the native and reverse orientation downstream from the minP BACH2. The addition of this sequence resulted in a threefold to fourfold increase in luciferase activity measured at D3 (Fig. 8a, upper panel) . A similar effect was observed when the BACH2 intronic sequence was ligated downstream from an independent promoter (minP PNL3.1 ) (Fig. 8a, middle panel). Finally, an additive effect on transcriptional activity was observed when 2 copies of the sequence were inserted in the plasmid (Fig. 8a, lower panel) conform to a functional enhancer sequence. We then studied the dynamic of its activity during naive B-cell activation and differentiation triggered by IL-2. For each time point analysed, the cells were electroporated 24 h before with the enhancer sequence in conjunction with minP BACH2 (Fig. 8b) or with minP PNL3.1 (Fig. 8c) . No activity was observed at D1 or in sorted D6 plasmablasts. Time course analysis however revealed the dynamic activation of the enhancer starting from D2, up to D4, with a peak at D3. Interestingly the kinetic activity of the enhancer mimicked the upregulation of BACH2 mRNA observed between D2 and D4, which was more Fig. 9 Role of the ELK1 binding motif in BACH2 enhancer. a ELK1 binding motif (core motif in blue) partially overlaps PU.1 predicted binding motif (core motif in red) within the enhancer of BACH2 intron 1. Positions refer to +1 transcription start site. Deletion of 21 nucleotides from the enhancer (Δ21 nt-Enh) or point mutations in the core motifs of PU1 binding site (Mut-PU1bs) or ELK1 binding site (Mut-ELK1bs) are underlined. b Luciferase activity of activated naive B cells electroporated with the wild-type enhancer (WT-Enh) or the enhancer deleted of 21 nucleotides (Δ21 nt-Enh), at different time points (D1, D2 and D3) and cultured for 24 h. Luciferase activity is presented relative to the cells electroporated with the BACH2 promoter (minP BACH2 ) alone (activity fixed to 1 for the different time points). Statistically significant cutoff value (dotted line) was obtained by adding 2 standard deviations to the mean value obtained for the promoter activity alone. c Luciferase activity measured at D3, 24 h after electroporation of reporter construct that carries the wild-type enhancer sequence (WT-Enh) and the derivative plasmids with mutations in PU1 core motif (Mut-PU1bs) or ELK1 core motif (Mut-ELK1bs). Luciferase activity is presented relative to the activity of the WT-Enh. (n = 3, mean ± s.e.m., ***p < 0.001, two-tailed unpaired Student's t-test). d Effect of IL-2 stimulation on the enhancer activity. Activated B cells were electroporated on D2 with the WT enhancer reporter construct and then stimulated (IL2) or not (No IL2) with IL-2 for 24 h in presence of MEK inhibitor (MEKi) or DMSO. Enhancer activity (fixed to 100 for the No IL2 condition) was determined relative to luciferase activity of the BACH2 promoter alone. (n = 6, mean ± s.e.m., **p = 0.007, two-tailed unpaired Student's t-test). e Kinetic of CFSE profiles. pronounced in the absence of IL-2 ( Fig. 2a) . These results suggested that this functional sequence might control BACH2 expression during the critical IL-2-mediated molecular switch responsible for early B cell engagement towards plasma cell differentiation.
ELK1 and cell division regulate BACH2 enhancer activity. We then tested the contribution of the ELK1 motif to the temporal activation of the enhancer. First we made serial deletions from the enhancer and measured the transcriptional activities at D3. Deletion of the ELK1 binding motif (positions +1367 to +1387, Supplementary Fig. 7 ) resulted in diminished luciferase activity almost equal to that of the minP BACH2 , in line with a positive role of ELK1 motif. Then, reporter constructs carrying the full-length enhancer (referred as WT-Enh) or the enhancer sequence deleted of 21 nucleotide (nt) corresponding to the ELK1 motif (referred as Δ21nt-Enh) (Fig. 9a) were transfected in activated B cells at different time points of the culture and luciferase activities were measured 24 h later (Fig. 9b) . We confirmed the positive role of the 21 nt sequence at D3 and D4 as its deletion resulted in diminished activity almost equal to that of the minP BACH2 . In contrast, analysis performed in D2-activated B cells showed lower enhancer activity compared to that performed at later time points, and the 21 nt deletion did not demonstrate any substantial effect on the luciferase activity (Fig. 9b ). These data indicated that different regulatory elements contributed to the enhancer function at different time point of the activation process.
In addition to the predicted binding motif for ELK1 in the 21 nt sequence, we identified a putative motif for PU.1 in the opposite strand of DNA, partially overlapping the ELK1 motif ( Fig. 9a) . To demonstrate the direct binding of ELK1 to its putative binding site and to exclude the possibility that PU.1 was responsible for the enhancer activity at D3, we performed point mutations in one of the two motifs. Inactive PU.1 motif (Mut-PU1bs) did not affect luciferase activity while inactive ELK1 motif (Mut-ELK1bs) led to a marked decreased of luciferase activity (Fig. 9c ). Thus ELK1 binding contributed to enhancer function.
Next we investigated the responsiveness of the enhancer to IL-2 signal at D3. In line with IL-2-induced BACH2 repression, we were able to show that IL-2 counteracts the enhancer activity although these experiments were done in heterogeneous cell populations (Fig. 9d ). By partially inhibiting the ERK signal in the presence of IL-2 we observed a significant rescue of enhancer activity (p < 0.05, t-test) suggesting that sustained ERK activity may be responsible for maintaining or switching ELK1 under its repressive form, although the possible involvement of other regulatory elements cannot formally be excluded. Thus we proposed that IL-2 stimulation is involved in the ELK1 switch from an activating to a repressive form following ERK activation above a threshold. A similar mechanism was described upon mitogenic stimulation by Yang et al. 42 .
ERK activity has been linked to B cell proliferation and some evidence suggests that B cells would integrate T cell derived signals, in addition to BCR signals, in a cell cycle-dependent 43 . Furthermore cell proliferation affects BACH2 expression 22 . Thus, to explore whether proliferation can modulate BACH2 expression and the enhancer activity, we profiled BACH2 expression and enhancer activity at D3 and D4 in sorted populations based on CFSE dilution (Fig. 9e ) and cell cycle (Hoechst staining). A marked difference in enhancer activity was observed in CFSE lo compared to CFSE hi cells at both time points (Fig. 9f, g) . In line with enhancer contribution to BACH2 expression, BACH2 levels mimicked enhancer activities with higher enhancer activity and BACH2 expression level being observed in CFSE hi Hoechst-negative (G0/G1 phases) cells compared to Hoechst-positive (S and G2/M phases) cells (Fig. 9f) . Collectively, these results characterize a BACH2 enhancer under ELK1 control that may contribute to maintain BACH2 expression, and when ERK activity becomes sustained with IL-2 stimulation and/or cell divisions, it may switch from an active to an inactive/repressive form, underlying the decline of BACH2 expression and plasma cell commitment (Fig. 10a ). Supporting this model, ELK1 contributed to the upregulation of BACH2 expression in the non-proliferative subset isolated at D4. In contrast, ELK1 repressed BACH2 expression in the CFSE lo cells stimulated with IL-2 ( Fig. 10b ).
Discussion
This study established a new link between early T cell help, intracellular signalling pathways, regulation of effector transcription factors expression and the B cell response through the characterisation of the IL2/ERK/ELK1/BACH2 axis which governs the B cell capacity to differentiate into plasma cell in a model system of primary human naive B cell culture. Strength in this model lies within the preliminary phase of activation as the full activation and proliferation of naive B cells in response to antigen-priming and T cell help (CD40L and cytokines) closely recapitulates the minimal initiation events observed during the first 4 days of an in vivo T cell-dependent response 44, 45 . The sustained presence of exogenous anti-BCR during this phase is reminiscent of the readily accessible antigen presented by dentritic cells within the interfollicular zone, while soluble CD40L and IL-2 recreate the consecutive interactions undertaken by cognate B and T cells in vivo 46, 47 . This T cell help activates B cells above a threshold required for eliciting plasma cell response, an effect mediated by BACH2 repression (Fig. 10a ). This finding is in accordance with the inversed relationship observed in mice between the strength of T cell help received by B cells in the GC and Bach2 expression levels 13 . This is also in line with the synergistic effect of IL-2 and IL-21 observed in our culture system confirming observations made by others 48 . IL-21 is presumed to be the most potent inducer of B cell terminal differentiation, an effect mediated by STAT3 activation and BCL6 repression 49, 50 . Beside its differentiation effect and unlike IL-2, IL-21 enhanced cell proliferation of human activated B cells, which complicate the study of the underlying molecular mechanisms. We decided therefore to focus our study on the minimal IL-2-mediated ERK signalling triggering plasma cell differentiation through BACH2 downregulation. We believe this IL-2/ERK axis could mimic in vivo situations when ERK is activated above a threshold potentially through different stimuli such as IL-4 or IL-15, or as a result of intense proliferation. In this context IL-21 that promotes proliferation may also contribute to the activation of this pathway. At least, a recent study demonstrated that antigen-primed murine B cells have a maximal 2-day window for acquisition of T cell help 51 . This finding is again in line with our study and the ability of human naive B cells to engage the plasma cell differentiation program in response to a very short duration of IL-2 stimulation within the first 2 days in culture (Fig. 2b ). This is also in coherence with the short half-life of this cytokine 52 and the transient secretion of IL-2 by the T cells 53, 54 .
Defined differentiation stimuli in our model system contributed to dissect heterogeneity in B cell responses, which is an important challenge in investigating B cell physiology. Using single-cell QPCR we found that only a small fraction of cells were early committed to plasma cell differentiation. Our integrating transcriptomic and BACH2 chromatin binding data allowed the identification of a BACH2 gene-signature in these cells, what revealed a significant BACH2 contribution at the early stage of B-cell activation. Some genes of this signature are known for their role in both the GC biology and lymphomagenesis. ATF5 for instance was found overexpressed in lymphoma and was recently associated with transformation to aggressive form of follicular lymphomas 55, 56 . Several members of the BCL2 family were found regulated by BACH2 in this study. Oncogenic processes may corrupt the balance of the apoptotic-signalling pathway under BACH2 control leading to cell proliferation and tumour progression. In fact, cumulative evidences exist for a role of BACH2 in lymphomagenesis, including the description of chromosomal translocations and mutations involving BACH2 in some lymphomas [57] [58] [59] .
Our study reveals a mechanism involved in the temporal regulation of BACH2 expression that control-B cell fate destiny (Fig. 10a ). In vivo BACH2 controls a specific time frame where AID expression/activity is fully efficient until PRDM1 expression is induced 6 . By taking in account those elements it is highly probable that BACH2 expression is finely regulated to enable immunoglobulin affinity maturation and to avoid unwanted genome-wide damages. In this study, our IL-2/ERK/BACH2 pathway fits with such fine-tune regulation of BACH2 expression. The enforced repression of BACH2 in recently activated B cells recapitulated the phenotypes reminiscent of Bach2-deficient B cells in mice: the unimpeded BLIMP1 induction, a higher frequency of differentiated cells and a defect of CSR 6 . The unimpeded PRDM1 expression could explain the impaired CSR observed in our model system. However beyond this mechanism we identified ID2 as a direct target of BACH2. ID2 inhibits E proteins such as E2A involved in AICDA (encoding AID) expression, thus regulating CSR 60, 61 . Therefore our study suggests that BACH2 expression may sustain AICDA expression through the repression of ID2.
Another insight into the effector functions of BACH2 at this early time point of B cell fate decision was its implication in mitochondrial metabolism and haeme homoeostasis. Herein we provide the first evidence that BACH2 regulates FECH expression encoding a key enzyme required for haeme synthesis. We propose a regulatory loop initiated by BACH2 repression, triggering haeme synthesis and consequently completing BACH2 inhibition by impairing its function.
Our data have shown that small differences in the expression levels of BACH2 at critical time point of B-cell activation have consequent effects on B cell fate. We characterised a novel BACH2 enhancer whose activity was dynamically regulated along the differentiation process. ELK1 was identified as the mediator of this IL-2-induced mechanism, accessing and binding to this new enhancer. ELK1 is a member of the ETS family of transcription factors at the crossroads of mitogen-activated protein kinase (MAPK) signalling cascades 62 . Its phosphorylation at S383 has mainly been studied, meanwhile different phosphorylation states and patterns of ELK1 exist and may vary with the stimuli triggering ERK activation thus determining the transcriptional response 63 . During the critical D2−D4 time window of BACH2 regulation, the BACH2 enhancer activity was under ELK1 positive control perhaps resulting from summed signal input integration (BCR, CD40L and TLR9 signalling). In contrast, IL-2 input seemed to repress both the transcriptional activity of the enhancer and BACH2 expression in ERK-dependent manner. Thus we propose that IL-2 signalling may be involved in ELK1 activatorrepressor switching following ERK activation above a threshold (Fig. 10a) . A similar mechanism was described earlier by Yang et al. 42 involving the temporal recruitment of corepressor complex depending on the dynamic phosphorylation status of ELK1. Collectively, our data suggest that this enhancer is important for BACH2 regulation in activated B cells and may provide a mechanism behind the Elk1-mediated upregulation of Prdm1 described earlier in a mouse model 23 .
In conclusion, our study has demonstrated a remarkably sensitive mechanism controlling the diversification and destiny of activated B cells. A short extrinsic input sustaining ERK activation initiates a molecular switch of ELK1 acting within the BACH2 super-enhancer and fine-tuning BACH2 expression. BACH2 regulates of a broad program of molecular and cellular processes that may have if disturbed potentially important implications for antibody response efficiency and in lymphomagenesis. Cell culture and cell sorting. Cell culture conditions, antibodies and flow cytometry procedures are as described in ref. 21 with a few modifications. All cultures were performed in complete medium consisting of RPMI 1640 (Invitrogen) supplemented with 10% FCS (Biowest) and antibiotics (Invitrogen). Apoptosis and proliferation were analysed using a PE-conjugated anti-active caspase-3 apoptosis kit (cat no. 550914 from BD Biosciences) and Click-IT Plus EdU Alexa Fluor 647 Flow cytometry assay kit (cat no. C10634 from ThermoFisher), respectively, according to the manufacturer's instructions. CFSE labelling of naive B cells was performed with 1 μM CFSE (Invitrogen) in serum free medium at 37°C for 10 min and washed in complete medium to follow cellular divisions (ModFIT analysis-VSH), and enable cell sorting of CFSE hi/lo populations. Purified naive B cells were cultured at 7.5 × 10 5 cells/ml in 24-well plates and stimulated during 4 days with 2.6 μg/ml F(ab′) 2 fragment goat anti-human IgA + IgG + IgM (H + L) (Jackson ImmunoResearch Laboratories), 100 ng/ml recombinant human soluble CD40L (NCI), 1.0 mg/ml CpG oligodeoxynucleotide 2006 (Cayla Invivogen), and 50 U/ml recombinant IL-2 (SARL Pharmaxie). ERK1/2 activation was inhibited with MEKi 0.5 μM (PD184161, Calbiochem). Day 4-activated B cells were washed and cultured at 4 × 10 5 cells/ml for up to 3 days with 50 U/ml IL-2, 12.5 ng/ml IL-10, and 5 ng/ml IL-4 (R&D Systems). All Abs used for flow cytometry analysis are listed in Supplementary Table 1 For QRT-PCR analyses and luciferase reporter assays, CFSE-stained B cells were collected at the required time point and cell sorted into CFSE hi/lo populations using FACsARIA (BD Biosciences). All flow cytometry gating strategies are shown in Supplementary Fig. 8 .
Methods
To identify the minimal time and duration for IL-2 stimulation during the activation phase, anti-IL-2 neutralising Ab or anti-IL-2 receptor α, β, γ Abs with their isotype controls (all from R&D Systems) were used at 10 μg/mL in the medium.
For IgM secretion assessed by ELISA, D6-differentiated cells were sorted as CD20 low CD38 hi and reseeded with IL-2, IL-4 and IL-10 at 5×10 5 cells/mL for 24 h. IgM antibodies were detected using AffiniPure Goat Anti-Human IgA + IgG + IgM (H + L) (Jackson Immuno-Reseach Laboratories) coated on 96-well plates, followed by secondary peroxydase-conjuged goat anti-human IgM (Jackson Immuno-Reseach Laboratories). Purified Chrompure Human IgM (Jackson Immuno-Reseach Laboratories) was used as standard. Plates were developed using TMB Substrate Reagent Set (BD Biosciences). For ELISPOT, D6-sorted plasmablasts (100 and 500 cells, in triplicate) were grown for 1 h in 96-well plates with anti-IgM coated membranes (SIGMA). Secreting cells were detected with secondary anti-human IgM-peroxydase antibody (SIGMA). For both experiments, D6-nondifferentiated B cells were used as negative control.
Cytologic analysis of differentiated cells was performed by preparing 10 5 D6-cells for microscopy using cytospin followed by May-Grumwald-Giemsa staining.
QRT-PCR analysis. RNA was extracted using RNeasy microkit (cat no. 74004 from Qiagen) and reversed transcribed into cDNA with Superscript II (Invitrogen). QRT-PCR was performed using the TaqMan Gene Expression Master Mix and run on the Step One Plus Real-time PCR System from Applied Biosystems. All TaqMan primers (Applied Biosystems) used in this study are listed in Supplementary  Table 2 . Gene expression levels were quantified using HPRT1 as endogenous control. The 2 exp(−ΔΔCt) method was used to determine the relative expression of each gene.
For single-cell QRT-PCR experiments, gene expression levels for the 16 selected Taqman assays within single-cell cDNA were measured with qPCR on 96.96 Dynamic Array IFC using the Fluidigm BioMark HD system. A total of 285 single cells from C1 captures were profiled using Dynamics Array IFC. Hierarchical clustering was performed on R version 3.2.4 with ComplexHeatmap (R package version 1.6.0), fluidigmSC (Fluidigm SINGuLAR Analysis Toolset, R package version 3.5.2), dendextend, amap (R package version 0.8-14) packages. We used a conservative Ct of 24 as LOD based on published guidelines 64 . Gene expression was defined on a log2 scale as: log2 expression = LOD-Ct. Samples were clustered by the Euclidean distance, and genes were clustered by the pearson distance. Heatmap was generated with the 'global_z_score' (normalisation by the expression value with the global mean and the global standard deviation).
Western blotting and DNA-binding ELISA. All antibodies used for western blotting are listed in Supplementary Table 3 . 0.8-1 × 10 6 primary naive B cells were recovered for protein extraction, which was performed using RIPA lysis buffer (Pierce) followed by cycles of sonication performed using the Biorupter Sonicator (Diagenode). Protein concentration was analysed using the BCA Protein Assay kit (cat no. 23225 from Pierce) and read by the Model 680 Microplate reader (Bio-Rad). Proteins were separated by the NuPAGE SDS-PAGE Gel system (Thermo Scientific) and transferred onto Immobilon-P PVDF membranes (Sigma-Aldrich) according to standard procedure. Detections were performed with HRPconjugated secondary Ab (Bio-Rad) and enhanced chemiluminescent (ECL Plus) reagent (Amersham) using the G:BOX Chemi imaging system (Syngene). GAPDH or β-ACTIN on the same membrane served as loading control. Uncropped original scans of immunoblots are provided in Supplementary Fig. 9 .
Sequence alignment and regulatory elements identification. MatInspector 65 , TFBIND 66 , TFSEARCH (http://cbrc3.cbrc.jp/papia/howtouse/howtouse_tfsearch. html), PROMO 67 and comparative genomics tool rVISTA 68 were used for the identification of regulatory elements in human BACH2 locus. BLAST program (NCBI) was used to search for alignment.
ChIP-QPCR assay and analysis. ChIP-IT PBMC kit (cat no. 53042 from Active Motif) was used according to the manufacturer's instructions. D3-activated naive B cells primed with IL-2 were fixed according to the protocol and lysed by sonication using the Epishear probe sonicator and the cooled sonication platform (Active Motif). Sonicated chromatin was controlled on gel prior to immunoprecipitation. Rabbit antibodies to ELK1 (ab32106), H3K9ac (ab4441), H3K27ac (ab4729), H3K4me1 (ab8895), p300 (ab10485) and IgG (ab37415) were from Abcam. Results were analysed with the ChIP-IT qPCR Analysis kit (cat no. 53029 from Active Motif) to calculate binding events detected per 1000 cells. Human Negative Control Primer Set1 and Human Positive Control Primer Set GAPDH − 2 from the ChIP-IT qPCR Analysis kit were used, other primers are listed in Supplementary Table 4 . siRNA experiments. All siRNAs (ON TARGET Plus, SMART Pool, Dharmacon) used in this study are listed in Supplementary Table 5 . 10 6 primary naive B cells per condition were recovered from culture for transfection using the Amaxa Cell Line Nucleofector Kit V (cat no. VCA-1003 from Lonza). Naive B cells were centrifuged at 1800 r.p.m. for 10 min at room temperature, re-suspended in transfection buffer and combined with 100 pmol of either target or control siRNA. Naive B cells were then electroporated using program O-17 of the Amaxa Nucleofector II Device (Lonza), re-suspended with pre-incubated media and cultured at 37 o C for 24 or 48 h. Transfection was optimised using a labelled siRNA control (AF647). 75% of the electroporated cells were positive 24 h after electroporation with 80-90% cell viability. Knockdown mRNA efficiency was determined for each siRNA by QRT-PCR and western blot analysis.
Luciferase reporter constructs. All oligonucleotides used in the construction of the BACH2 luciferase reporter plasmids were designed using Primer3 and synthesised by Eurogentec. The list of cloning and sequencing primers is available in Supplementary Table 6 . DNA insert sequences were amplified by PCR using Q5 High-Fidelity DNA polymerase (NEB) with primers containing restriction sites followed by PCR product purification (NucleoSpin Gel and PCR Clean-up, Machery-Nagel). Purified insert DNAs together with the appropriate expression vectors were then restriction digested using corresponding enzymes (CutSmart restriction endonucleases, NEB), purified and ligated together using T4 DNA ligase (Roche). The reporter vectors implemented for DNA insertion were the basic vector pNL1.1[Nluc] and minimal promoter vector pNL3.1[Nluc/minP] that both encoded the NanoLuc luciferase reporter gene (Promega). The pGL4.50[luc2/ CMV/Hygro] vector (Promega) encoding the Firefly luciferase reporter gene luc2 (Photinus pyralis) was used for transfection efficiency. Escherichia coli cells (MAX Efficiency DH5α Competent cells, Invitrogen) were transformed with the recombinant plasmid DNA and individual colonies were then screened for the presence of the DNA insert by PCR (Taq DNA Polymerase with ThermoPol Buffer, NEB). Positively identified clones were sent for Sanger sequencing analysis. NCBI BLAST confirmed the absence of mutations. Finally, the selected plasmid DNA clones were further expanded and purified (NucleoBond Xtra Midi Plus EF, Machery-Nagel).
The luciferase reporter containing the BACH2 minimal promoter (−725; +146), pNL1.1/minP BACH2 , was constructed through PCR amplification from tonsil B cell DNA as previously described by ref. 41 , followed by NheI/XhoI restriction digestion and ligation into the pNL1.1 [Nluc] vector.
The luciferase reporter vector containing the 228 bp (+1265; +1493) BACH2 enhancer (Enh), pNL1.1/minP BACH2 /Enh, was constructed through PCR amplification from the PAC clone RP1-104D1 followed by XhoI restriction digestion and downstream ligation into the BACH2 minimal promoter construct pNL1.1/minP BACH2 . The enhancer was then sub-cloned from pNL1.1/minP BACH2 / Enh and ligated into the XhoI site of the independent minimal promoter vector pNL3.1[Nluc/minP] to generate minP PNL3.1 /Enh. All enhancer inserts were screened by PCR to identify sequence ligations in both the 5′-3′ and 3′-5′ orientation. Sequencing confirmed the orientation of inserts.
The remaining luciferase reporter constructs containing fragmented sequences of the BACH2 enhancer, namely Enh80 (+1265/+1366), Enh122 (+1388/+1493) and Enh115 (+1265/+1381) were generated by PCR amplification with primers containing XhoI restriction sites at the 5′end and ligation into pNL1.1/minP BACH2 . pNL1.1/minPBACH2/Δ21nt-Enh was generated by sub-cloning the Enh122 sequence by blunt ended ligation into the EcoRV site of the pNL1.1/ minP BACH2 /Enh80 vector. All fragmented enhancer inserts were screened by PCR to identify sequence ligations in both the native 5′-3′ and reverse 3′-5′ orientation.
For preparation of the mutant Mut-PU1bs and Mut-ELK1bs forms of the enhancer, pNL3.1/Enh was implemented as DNA template for PCR site-directed mutagenesis (Q5 Site-Directed Mutagenesis Kit, cat no. E0554 from NEB). The presence of the substitution mutations within the enhancer was confirmed by sequencing. The mutated enhancer sequences were then sub-cloned by XhoI restriction digestion into the XhoI site of pNL1.1/minP BACH2 to generate pNL1.1/ minP BACH2 /Mut-PU1bs and pNL1.1/minP BACH2 /Mut-ELK1bs.
Luciferase reporter assays. The following luciferase assay experiments were performed on primary naive B cells, transfected using the Amaxa Cell Line Nucleofector Kit V (cat no. VCA-1003 from Lonza) and cultured under the conditions of the in vitro B cell differentiation model. Depending on the day of electroporation between 1.0 and 5.0 × 10 6 B cells were re-suspended in transfection buffer and combined with 4-5 μg of appropriate BACH2 containing NanoLuc reporter vectors together with 1 μg of control plasmid, pGL4.50[luc2/CMV/Hygro]. B cells were electroporated using program O-17 of the Amaxa Nucleofector II Device (Lonza), re-suspended with pre-incubated media and cultured at 37°C for 24 h. 40% transfection efficiency was observed with 2 μg pmax-GFP and~80-90% cell viability with 2-4 μg DNA. Cells were then collected, washed with PBS and centrifuged at 1800 r.p.m. (×2). Finally the cells were lysed in 50 μL 1X Passive Lysis Buffer (Promega) for 15 min at room temperature followed by storage of the lysate at −80°C. The Nano-Glo Dual-Luciferase reporter Assay system (Promega) was used to detect luciferase expression from the NanoLuc and pGL4.50[luc2/ CMV/Hygro] reporter vectors within lysate samples using the luminometer of the Varioskan Flash Multimode Reader (Thermo Scientific). The luciferase expression values, read as relative light units (RLU), from both reporter vectors were averaged and NanoLuc was normalised to firefly luciferase. Ratios of RLU were then normalised to that of control promoterless condition (pNL1.1) or minP BACH2 or minP PNL3.1 .
For the kinetic experiments of pNL1.1/minP BACH2 /Enh and pNL3.1/Enh, naive B cells were electroporated starting from D0 through to D5. D6 plasmablasts were initially electroporated on D4 and cell sorted as CD20 lo CD38 hi cells on D6. For the kinetic experiment of pNL1.1/minP BACH2 /Δ21nt-Enh, activated B cells were electroporated between D1-D4. Following each electroporation, transfected cells were placed back into the stimulation medium that corresponded with the two-step culture system and the luciferase activity of all the constructs was determined 24 h later (or 48 h for D6 plasmablasts).
To determine the effect of IL-2 on the BACH2 enhancer in total activated B cells, cells were electroporated on D2 with pNL1.1/minP BACH2 /Enh (native orientation) and subsequently placed back into culture with or without IL-2 for 24 h. For identification of the sub-population of dividing and proliferating cells, naive B cells stained with CFSE on D0 were electroporated on D2 with pNL1.1/ minP BACH2 /Enh (native orientation) and cultured for 24 h and 48 h. On D3, cells were stained with Hoechst and sorted into three populations CFSE hi H − , CFSE hi H + and CFSE lo . On D4, cells were sorted on CFSE staining alone into CFSE hi and CFSE lo populations.
RNA-seq. Three experiments from independent blood donors were analysed. RNA extractions were performed with the NucleoSpin RNA XS kit (cat no. 740902.250 from Macherey-Nagel). QC, library preparation and sequencing were performed by Helixio company (Clermont Ferrand, France). Briefly, libraries were prepared with the TruSeq Stranded mRNA Library Prep Kit (cat no. RS-122-2101 from Illumina) and samples were sequenced on an Illumina NextSeq 500 using 75-bp single-end reads (NextSeq 500 High Output v2, Illumina). Quality of sequencing data was monitored by FastQC. Residual adapters from sequencing were trimmed using cutadapt 1.0. Potential PCR duplicates were removed using SAMtools 1.3. Reads were then aligned on the GRCh38 human genome using STAR 2.4.2a. Differential expression on filtered genes (HTSfilter 1.7.1), were performed using DESeq2 in R 3.3.1. Genes were declared differentially expressed with a false discovery rate < 5%. For heatmap, genes differentially expressed with fold change >1.4 in CD25 hi and siBACH2 condition compare to CFSE lo population was ploted. Log2 normalised read counts from DESeq2 were used to generate the representation with gplots 3.0.1, and RColorBrewer 1.1-2. Hierarchical clustering was generated using Euclidean distance matrix with complete linkage.
ChIP-seq. BACH2 antibody performance used for the ChIP (D3T3G, Cell signalling) was certified by Active Motif Epigenetic Services. Activated naive B cells at D3 of the culture were fixed with 1% formaldehyde for 15 min at room temperature. Cross-linking was quenched with Glycerine. For immunoprecipitation, 28 μg of chromatin and 40 μL of antibody were used. Control, siBACH2 and input were sequenced and aligned on hg19. For comparative analysis, standard normalisation is achieved by down-sampling the usable number of tags for each sample in a group to the level of the sample in the group with the fewest usable number of tags. Peaks were called using the MACS 2.1.0 algorithms 69 . MACS default cutoff is p-value 1e-7 for narrow peaks and 1e-1 for broad peaks. Peak filtering was performed by removing false ChIP-seq peaks as defined within the ENCODE blacklist 70 .
Known motifs were identified with the findMotifsGenome program of the HOMER package 71 using default parameters and input sequences comprising ±100 bp from the centre of the top 1000 peaks.
BACH2 target analysis was realized using BETA 72 using the default parameters with differential gene expression data set (siBACH2 vs. uncommitted B cells, p < 0.05) and ChIP-seq data.
Statistical analyses. GraphPad Prism software was used for statistical analysis using the Mann−Whitney non-parametric test or the two-tailed unpaired Student's t-test if not stated otherwise.
Data availability. The data supporting the findings of this study are available within the article and its Supplementary Information files, or are available on reasonable request from the corresponding authors. RNA-seq and ChIP-seq data have been deposited in Gene Expression Omnibus with the primary accession code GSE102460.
